Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs TXG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: VCYT 5 – 1 TXG Matrix Metrics: VCYT 6 – 4 TXG

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over 10x Genomics, Inc. (TXG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas TXG carries 50.5/100 (HOLD) at $54.99 (N/M Forward P/E, -10.6% operating margin).

  • Composite vs. Pillar Nuance: While TXG currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. VCYT 49.1/100 HOLD), VCYT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.0% vs. -10.6% operating margin) and revenue trajectory (+15.1% vs. +1.1% YoY).
  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile TXG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs TXG
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
TXG NASDAQ
10x Genomics, Inc. Class A Common Stock
Laboratory Analytical Instruments
$54.99
-5.5% 1D
Market Cap $7.7B
TTM Revenue $619M
Forward P/E N/M
Beta / 30D Vol 2.70β · 109% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 51.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 36.7 · SMA20: $67.43 · SMA50: $73.77

6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 TXG)

Columns: Metric · VCYT · TXG
1. Valuation Multiples VCYT
Forward P/E 15.3x N/M
Trailing P/E 15.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.1x 11.6x
2. Growth & Scale VCYT
Revenue Growth (YoY) +15.1% +1.1%
Earnings Growth (YoY) +58.3% +0.0%
TTM Revenue (USD) $582M $619M
Market Cap $2.0B $7.7B
3. Profitability & Quality VCYT
Gross Margin 74.2% 72.0%
Operating Margin 15.0% -10.6%
Net Profit Margin 21.8% -10.8%
Return on Equity (ROE) 9.4% -8.3%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M $94M
Cash Flow Margin 27.8% 15.2%
Net Cash / Leverage $159M Net Cash $450M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCYT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 197.3% (47th %ile) 91.0% (42nd %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.71x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TXG
OpEx & R&D Intensity 59.2% of Rev ($344M) 82.6% of Rev ($511M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Concentrated Oligopoly Moat
Supply-Chain Role Diagnostics & Research Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (6) vs TXG (4)
Institutional Metric VCYT TXG Criterion Row Edge
Market Capitalization
Scale
$2.0B $7.7B Larger Scale TXG
Trailing P/E Ratio
Valuation
15.8x N/M Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x N/M Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% +1.1% Higher Growth VCYT
Operating Margin (TTM)
Profitability
15.0% -10.6% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% -10.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -8.3% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 46% ($15–$103) Stronger Trend TXG
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 2.70β · 109% Vol Lower Realized Risk TXG
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite TXG
Trailing 12M Revenue (USD)
Operating Scale
$582M $619M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 72.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 11.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) $94M ($450M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TXG +23.03 pp
VCYT: -44.32% · TXG: -21.29%
3M Horizon TXG +39.83 pp
VCYT: -40.98% · TXG: -1.15%
6M Horizon TXG +198.5 pp
VCYT: -42.14% · TXG: +156.36%
1Y Horizon TXG +276.11 pp
VCYT: -39.78% · TXG: +236.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue TXG Revenue VCYT Op. Margin TXG Op. Margin Margin Leader
FY2018 $90M $150M -24.2% -75.7% VCYT
FY2019 $120M $250M -12.6% -12.4% TXG
FY2020 $120M $300M -30.1% -178.7% VCYT
FY2021 $220M $490M -37.3% -10.7% TXG
FY2022 $300M $520M -13.9% -32.5% VCYT
FY2023 $360M $620M -23.8% -42.9% VCYT
FY2024 $450M $610M 3.6% -31.9% VCYT
FY2025 $520M $640M 11.2% -9.5% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TXG CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 91.0%
IV Percentile 42nd %ile
Put/Call OI Skew 0.71x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TXG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
TXG Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $7.7B market capitalization and -10.6% operating margin.
OpEx & R&D Reinvestment 82.6% of Rev ($511M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ VCYT vs TXG Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over 10x Genomics, Inc. (TXG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas TXG carries 50.5/100 (HOLD) at $54.99 (N/M Forward P/E, -10.6% operating margin). Composite vs. Pillar Nuance: While TXG currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. VCYT 49.1/100 HOLD), VCYT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.0% vs. -10.6% operating margin) and revenue trajectory (+15.1% vs. +1.1% YoY). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile TXG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with TXG at +1.1% YoY revenue growth and +0.0% YoY earnings growth on $619M TTM revenue (72.0% gross margin, -10.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while TXG shifted +326.7%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 82.6% of Rev ($511M) (0 disclosures) for TXG.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas TXG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.6x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus TXG (-8.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, TXG carries 91.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.70β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.